Empirical Financial Services LLC d.b.a. Empirical Wealth Management Acquires New Shares in Inhibrx, Inc. (NASDAQ:INBX)

Empirical Financial Services LLC d.b.a. Empirical Wealth Management purchased a new position in shares of Inhibrx, Inc. (NASDAQ:INBX - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 22,584 shares of the company's stock, valued at approximately $348,000. Empirical Financial Services LLC d.b.a. Empirical Wealth Management owned about 0.16% of Inhibrx at the end of the most recent reporting period.

Separately, Exchange Traded Concepts LLC bought a new stake in shares of Inhibrx in the fourth quarter worth about $148,000. Institutional investors and hedge funds own 82.46% of the company's stock.

Insider Buying and Selling at Inhibrx

In other news, Director Jon Faiz Kayyem purchased 69,686 shares of Inhibrx stock in a transaction that occurred on Tuesday, November 19th. The stock was acquired at an average cost of $14.23 per share, for a total transaction of $991,631.78. Following the purchase, the director now directly owns 51,093 shares of the company's stock, valued at $727,053.39. This trade represents a -374.80 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 22.20% of the company's stock.

Analyst Ratings Changes

Separately, JMP Securities reaffirmed a "market perform" rating on shares of Inhibrx in a research note on Wednesday, January 22nd.

Inhibrx Stock Up 7.8 %

INBX stock traded up $0.96 during mid-day trading on Thursday, reaching $13.27. The company had a trading volume of 37,482 shares, compared to its average volume of 83,808. Inhibrx, Inc. has a 52 week low of $10.80 and a 52 week high of $18.95. The stock has a 50 day simple moving average of $14.50 and a two-hundred day simple moving average of $14.64.

Inhibrx Profile

Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.